Atazanavir

Major

Atazanavir Entrectinib Rozlytrek Increased entrectinib exposure, an increased frequency or severity of adverse reactions including increased risk of cardiac arrhyt... Details Atazanavir Eribulin Injection Halaven An increased risk of QT interval prolongation Details Atazanavir Esomeprazole Nexium Reduced atazanavir exposure, reduced efficacy of atazanavir and development of resistance Details Atazanavir Esomeprazole Injection Nexium Reduced atazanavir exposure, reduced efficacy of atazanavir and development of resistance Details Atazanavir Famotidine Calmicid Reduced atazanavir exposure and an increased risk of QT interval prolongation Details Atazanavir Famotidine Injection Calmicid Reduced atazanavir exposure and an increased risk of QT interval prolongation Details Atazanavir Felbamate Felbatol An increased risk of QT interval prolongation Details Atazanavir Felodipine Plendil® An increased calcium channel blocker exposure Details Atazanavir Fentanyl Transdermal Patch Duragesic® Increased fentaNYL exposure and an increased risk of prolonged opioid effects Details Atazanavir Finerenone Kerendia Increased finerenone exposure and an increased risk of finerenone-related adverse effects Details Atazanavir Flecainide Tambocor® Increased antiarrhythmic exposure and an increased risk of QT interval prolongation Details Atazanavir Fluvastatin Lescol Increased HMG-CoA reductase inhibitor exposure Details Atazanavir Foscarnet Injection Foscavir Increased risk of QT interval prolongation Details Atazanavir Fostamatinib Tavalisse Increased fostamatinib active metabolite (R406) exposure and an increased risk of fostamatinib-related adverse effects (eg., hepat... Details Atazanavir Fostemsavir Rukobia Increased risk of torsade de pointes Details Atazanavir Galantamine Razadyne An increased risk of QT interval prolongation Details Atazanavir Gatifloxacin Ophthalmic Zymar® An increased risk of QT interval prolongation Details Atazanavir Gemifloxacin Factive An increased risk of QT interval prolongation Details Atazanavir Glasdegib Daurismo Increased risk of QT interval prolongation Details Atazanavir Goserelin Implant Zoladex Increased risk of QT interval prolongation Details Atazanavir Granisetron Transdermal Patch Sancuso An increased risk of QT interval prolongation Details Atazanavir Granisetron Injection Granisol An increased risk of QT interval prolongation Details Atazanavir Histrelin Implant Supprelin Increased risk of QT interval prolongation Details Atazanavir Hydrocortisone Ala-Cort Increased corticosteroid exposure and an increased risk of corticosteroid-related adverse effects Details Atazanavir Hydrocortisone Injection A-Hydrocort® Increased corticosteroid exposure and an increased risk of corticosteroid-related adverse effects Details Atazanavir Hydroxychloroquine Plaquenil Increased risk of QT interval prolongation Details Atazanavir Ibrutinib Imbruvica Increased ibrutinib exposure Details Atazanavir Ifosfamide Injection Ifex Decreased ifosfamide effectiveness Details Atazanavir Infigratinib Truseltiq Increased infigratinib plasma concentrations Details Atazanavir Inotuzumab Ozogamicin Injection Besponsa Increased risk of QT interval prolongation Details Atazanavir Ivabradine Corlanor Increased exposure of ivabradine and increased risk of QT prolongation Details Atazanavir Lacosamide Injection Motpoly An increased risk of PR interval prolongation, AV block, bradycardia, and ventricular tachyarrhythmia Details Atazanavir Lansoprazole Prevacid Reduced atazanavir exposure, reduced efficacy of atazanavir and development of resistance Details Atazanavir Lenacapavir Injection Sunlenca Increased lenacapavir exposure, increased atazanavir exposure and an increased risk of atazanavir-related adverse reaction Details Atazanavir Lenacapavir Oral Sunlenca Increased lenacapavir exposure, increased atazanavir exposure and an increased risk of atazanavir-related adverse reaction Details Atazanavir Lenvatinib Lenvima Increased risk of QT-interval prolongation Details Atazanavir Letermovir Injection Prevymis Increased CYP3A substrate exposure Details Atazanavir Levofloxacin Levaquin Increased risk of QT interval prolongation Details Atazanavir Levofloxacin Injection Levaquin Increased risk of QT interval prolongation Details Atazanavir Loperamide Diamode Increased loperamide exposure, an increased risk of loperamide-related adverse effects and an increased risk of QT interval prolon... Details